As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2025 about ICH M15: General Principles for Model-Informed Drug Development can be found below.
As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2025 about ICH M15: General Principles for Model-Informed Drug Development can be found below.